Table II.
Associations of baseline patient characteristics with vascular access subgroups
| All AVF | All AVG | |||||
|---|---|---|---|---|---|---|
| Parameter | AVF w/ interv |
AVF w/o interv |
Odds ratio (95% CI) |
AVG w/ interv |
AVG w/o interv |
Odds ratio (95% CI) |
| N patients | 146 | 143 | 55 | 255 | ||
| Age ≥65 yr, N (%) | 28 (19%) | 26 (18%) | 1.07 (0.59–1.93) | 14 (25%) | 62 (24%) | 1.06 (0.54–2.08) |
| Female, N (%) | 67 (46%) | 32 (22%) | 2.94 b (1.75–5.00) | 31 (56%) | 141 (55%) | 1.04 (0.58–1.88) |
| Black race, N (%) | 125 (86%) | 120 (84%) | 1.14 (0.60–2.17) | 50 (91%) | 229 (90%) | 1.14 (0.42–3.10) |
| DM, N (%) | 77 (53%) | 55 (38%) | 1.74 a (1.09–2.79) | 26 (47%) | 149 (58%) | 0.66 (0.37–1.19) |
| HTN, N (%) | 138 (94%) | 132 (92%) | 1.18 (0.44–3.14) | 47 (85%) | 243 (95%) | 0.33 a (0.12–0.89) |
| CAD, N (%) | 46 (32%) | 42 (29%) | 1.08 (0.66–1.79) | 24 (44%) | 72 (28%) | 2.03 a (1.11–3.71) |
| PVD, N (%) | 26 (18%) | 19 (13%) | 1.39 (0.73–2.65) | 16 (29%) | 45 (18%) | 1.96 (1.01–3.83) |
| CVD, N (%) | 25 (17%) | 27 (19%) | 0.88 (0.48–1.60) | 14 (25%) | 54 (21%) | 1.30 (0.66–2.57) |
| CHF, N (%) | 45 (31%) | 44 (31%) | 0.99 (0.60–1.64) | 16 (29%) | 83 (32%) | 0.87 (0.46–1.66) |
| Obese, N (%)c | 58 (41%) | 41 (31%) | 1.55 (0.94–2.56) | 18 (38%) | 85 (37%) | 1.01 (0.53–1.92) |
| Ipsilateral CVC, N (%) | 45 (31%) | 47 (33%) | 0.91 (0.55–1.49) | 14 (25%) | 71 (28%) | 0.81 (0.57–1.15) |
| Comorbid score ≥4, N (%) | 53 (36%) | 40 (28%) | 1.47 (0.89–2.41) | 23 (42%) | 102 (40%) | 1.08 (0.60–1.95) |
| Antiplatelet drug, N (%) | 58 (40%) | 44 (31%) | 1.45 (0.89–2.37) | 19 (34%) | 91 (36%) | 0.97(0.52–1.80) |
AVF, arteriovenous fistula; AVG, arteriovenous graft; Interv, intervention; DM, diabetes; HTN, hypertension; CAD, coronary artery disease; PVD, peripheral vascular disease; CVD, cerebrovascular disease; CHF, congestive heart failure.
a
P < .05
b
P < .001
c
missing values for 52 patients